1. 43. 65 Fed. Reg. 60328–60332 (Oct. 10, 2000).
2. 25. Sources of concern range from the original Asilomar moratorium on recombinant DNA research to discussions of germ-line interventions, both deliberate and inadvertent. See, e.g., the many sources cited in the Human Gene Therapy Scope Note, supra note 10.
3. 53. which had a stake in the success of the trial's liver-directed gene transfer methodology, developed by his laboratory at Penn. See Nelson, D. Weiss, R. , “Hasty Decisions in the Race to a Cure?,” Washington Post, Sunday, Nov. 1999; at A01, for a review of the potential financial conflicts of interest and how they were viewed before Mr. Gelsinger's death.
4. 34. RAC meeting, at (last visited September 17, 2002).
5. 52. Dr. Wilson, James , then-director of the University of Pennsylvania's Institute for Human Gene Therapy, where the ornithine transcarbamylase deficiency trial took place, and a co-investigator, had a financial interest in a company he founded, Genovo Inc.